Displaying drugs 11076 - 11100 of 11535 in total
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green ... A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing. …
MDX-1379
MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Investigational
Depatuxizumab mafodotin
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Investigational
Rimiducid
Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins...
Investigational
Matched Description: … Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. …
Otelixizumab
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that...
Investigational
Matched Description: … Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which …
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Matched Description: … It is also a potential therapy for COVID-19. ... This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding …
Tesofensine
Investigational
Refametinib
Investigational
PRX-07034
Investigational
Zalutumumab
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal …
PZM21
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
Matched Description: … PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment …
EGT-101
EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.
Investigational
Matched Description: … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A. …
Methapyrilene
Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Withdrawn
Matched Description: … Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. …
SB-249553
SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Investigational
Matched Description: … SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. …
Telisotuzumab vedotin
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Investigational
Matched Description: … Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety …
ONO-8539
ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).
Investigational
Matched Description: … ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal …
Reloxaliase
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
Matched Description: … Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. …
Fonadelpar
Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
Investigational
Matched Description: … Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness …
SLV319
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
NXN-188
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase …
Octopamine
Octopamine is structurally similar to norepinephrine. It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.
Experimental
Matched Description: … It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World …
Clinafloxacin
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … Clinafloxacin is a fluoroquinolone antibacterial currently under research. …
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of …
Modimelanotide
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
Rocapuldencel-T
Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).
Investigational
Matched Description: … Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A …
Displaying drugs 11076 - 11100 of 11535 in total